1-amino-3-methyl-5-phenyl adamantane | 651311-87-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-amino-3-methyl-5-phenyl adamantane
• 英文别名: 3-Methyl-5-phenyladamantan-1-amine
• CAS: 651311-87-4
• 化学式: C₁₇H₂₃N
• 分子量: 241.376
• InChiKey: NMLWLANWDKUOBD-UHFFFAOYSA-N

物化性质

• 沸点：
  337.5±21.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。
• NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
  申请人：——

  公开号：US20040019118A1

  公开（公告）日：2004-01-29

  Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemic-ally-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.

  氨基环己烷和氨基烷基环己烷化合物作为NMDA受体拮抗剂在系统上具有活性，对抑制微管相关蛋白tau异常过度磷酸化有效。涉及治疗由于或与微管相关蛋白tau异常过度磷酸化相关的疾病的方法，以及包含这些化合物的药物组合物。
• [EN] METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR AMÉLIORER LA FONCTION COGNITIVE
  申请人：GALLAGHER MICHELA

  公开号：WO2014153180A1

  公开（公告）日：2014-09-25

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5 -containing GABAA receptor agonist in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

  本发明涉及用于治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法和组合物。具体而言，它涉及在需要或有风险的受试者中使用含有a5的GABAA受体激动剂与美拉替特或其衍生物或类似物结合，用于治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患上与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症或躁郁症、肌萎缩侧索硬化、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症、强迫行为和物质成瘾。
• METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE
  申请人：Hung David T.

  公开号：US20100152108A1

  公开（公告）日：2010-06-17

  The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.

  该发明提供了一种治疗和/或预防和/或减缓阿尔茨海默病的发作和/或发展的方法和联合疗法，使用氢化吡啶并哌啶(例如二甲苯胺)与另一化合物、其药用盐或治疗阿尔茨海默病的疗法结合。
• Novel treatment for alzheimer's disease
  申请人：EPFL Ecole Polytechnique Fédérale de Lausanne

  公开号：EP2111858A1

  公开（公告）日：2009-10-28

  The present invention concerns a new pharmaceutical composition comprising an antagonist and a co-agonist of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). The inventors found that the co-administration of these two compounds effectively inhibits production of amyloide-β peptide. In patient's suffering from Alzheimer's disease, these peptides are deposited in the extracellular matrix forming neuritic "plaques". Therefore, the present inventors identified a new possibility for prophylaxis and/or treatment of Alzheimer's disease by stopping the continued formation of neuropathological extracellular deposits.

  本发明涉及一种新的药物组合物，包括N-甲基-D-天门冬氨酸型谷氨酸受体（NMDAR）的拮抗剂和共激动剂。发明人发现这两种化合物的联合使用有效地抑制了淀粉样β肽的产生。在患有阿尔茨海默病的患者中，这些肽沉积在细胞外基质中形成神经突起“斑块”。因此，本发明人发现了一种新的预防和/或治疗阿尔茨海默病的可能性，即通过阻止神经病理性细胞外沉积物的持续形成。